S-Equol in Alzheimer's Disease (SEAD) Trial

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).

Key facts

Study ID

NCT02142777

Run by

Russell Swerdlow, MD

People needed

15

Starts

2014-07-01

Expected to finish

2016-04-01

Last updated by the study team

2016-08-16

Who can join

Age: 60 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Very mild (CDR 0.5) or mild (CDR 1) AD at time of last KU ADC assessment
• Have a study partner
• Speak English as primary language

You may not qualify if…

• No viable study partner
• Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
• Use any type of estrogen replacement therapy

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.